Ra Capital Management as of Sept. 30, 2015
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 47 positions in its portfolio as reported in the September 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | 11.6 | $81M | 12M | 6.91 | |
| Axovant Sciences | 9.3 | $65M | 5.0M | 12.92 | |
| Dyax | 7.0 | $49M | 2.6M | 19.09 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 4.9 | $34M | 1.6M | 22.11 | |
| Tg Therapeutics (TGTX) | 4.5 | $32M | 3.1M | 10.08 | |
| Regulus Therapeutics | 3.8 | $26M | 4.0M | 6.54 | |
| Coherus Biosciences (CHRS) | 3.8 | $26M | 1.3M | 20.04 | |
| Ascendis Pharma A S (ASND) | 3.7 | $26M | 1.5M | 17.70 | |
| Zogenix | 3.3 | $23M | 1.7M | 13.50 | |
| Aquinox Pharmaceuticals | 3.1 | $22M | 1.5M | 14.07 | |
| Proteon Therapeutics | 3.0 | $21M | 1.5M | 13.91 | |
| Aimmune Therapeutics | 2.9 | $20M | 790k | 25.32 | |
| Dicerna Pharmaceuticals | 2.9 | $20M | 2.4M | 8.21 | |
| Global Blood Therapeutics In | 2.8 | $19M | 457k | 42.16 | |
| Blueprint Medicines (BPMC) | 2.7 | $19M | 878k | 21.34 | |
| Ardelyx (ARDX) | 2.6 | $18M | 1.1M | 17.28 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 2.2 | $15M | 1.2M | 12.72 | |
| Bluebird Bio (BLUE) | 2.1 | $14M | 167k | 85.55 | |
| BioCryst Pharmaceuticals (BCRX) | 2.0 | $14M | 1.2M | 11.40 | |
| Intra Cellular Therapies (ITCI) | 1.8 | $13M | 314k | 40.04 | |
| Pronai Therapeutics | 1.8 | $12M | 605k | 20.52 | |
| Alcobra | 1.6 | $11M | 1.8M | 6.04 | |
| Therapeuticsmd | 1.3 | $8.9M | 1.5M | 5.86 | |
| Neuroderm Ltd F | 1.3 | $8.8M | 425k | 20.67 | |
| Natera (NTRA) | 1.2 | $8.5M | 784k | 10.85 | |
| Xencor (XNCR) | 1.2 | $8.3M | 680k | 12.23 | |
| Sangamo Biosciences (SGMO) | 1.2 | $8.2M | 1.4M | 5.64 | |
| Tenax Therapeutics | 1.1 | $8.0M | 2.7M | 3.00 | |
| Nivalis Therapeutics | 1.1 | $7.9M | 613k | 12.97 | |
| Zynerba Pharmaceuticals | 1.1 | $7.5M | 525k | 14.31 | |
| Seres Therapeutics (MCRB) | 1.1 | $7.3M | 247k | 29.64 | |
| Akari Therapeutics | 0.9 | $6.3M | 264k | 24.00 | |
| Ultragenyx Pharmaceutical (RARE) | 0.8 | $5.4M | 56k | 96.31 | |
| Alnylam Pharmaceuticals (ALNY) | 0.7 | $5.1M | 63k | 80.36 | |
| Bellicum Pharma | 0.7 | $4.6M | 316k | 14.53 | |
| Agile Therapeutics | 0.6 | $4.3M | 631k | 6.74 | |
| Arca Biopharma | 0.6 | $4.0M | 811k | 4.96 | |
| Vitae Pharmaceuticals | 0.5 | $3.5M | 321k | 11.01 | |
| Epizyme | 0.4 | $2.9M | 227k | 12.86 | |
| Auris Med Hldg | 0.2 | $1.7M | 468k | 3.56 | |
| Applied Genetic Technol Corp C | 0.2 | $1.6M | 121k | 13.14 | |
| Novavax | 0.2 | $1.1M | 162k | 7.07 | |
| Vical Incorporated | 0.1 | $959k | 2.1M | 0.46 | |
| Benitec Biopharma Ltd spons | 0.1 | $864k | 141k | 6.15 | |
| DURECT Corporation | 0.1 | $745k | 382k | 1.95 | |
| Wafergen Bio-systems | 0.0 | $279k | 205k | 1.36 | |
| Ampliphi Biosciences | 0.0 | $257k | 65k | 3.95 |
